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The use of haplo-identical transplant (HIT) with positive stem cell selection using the CLINIMACS System has been recently introduced in our Bone Marrow Transplant Unit as an alternative treatment for patients (pts) lacking on HLA-compatible family or unrelated donor. The aim of this study is to analyse the most frequent complications and to reveal the nursing practices performed in this patient population. The methodology performed was the clinical charts analysis and bibliographic survey. Since January 1999, eight pts were submitted to HIT in our Unit. During the transplant (first admission) the nursing care of these pts differs from conventional allogeneic transplants in the following points: 1-Longer period of isolation in HEPA filtered rooms; 2-More attention is given to possible complications, namely infections; 3-Education of the family in relation with emergent complications; 4-Number of visitors per day is limited to one visitor. Nursing care also plays an essential role in the prevention, early diagnosis and treatment of arising complications. In the posttransplant period, 7 of the 8 pts were readmitted due to the following complications: CMV blood isolation (n=5), acute Graft Versus Host Disease (GVHD) following donor lymphocytes infusion (n=1), seizure in the setting of GVHD treatment (n=1). Two of 5 pts admitted with CMV positivity died with relapse of AML and CMV pneumonitis. The frequent readmission of these patients due to complications post-transplant further stresses the important role played by the nursing team in the care of pts submitted to HIT. Therefore the focus of our intervention is to assure a rigorous accomplish to infection control procedures, toxicity surveillance, as well as to give nurse care to severely immunodepressed pts. Consequently we need to be watchful of emerging symptoms and signs. We also need more time and availability to study and know what pattern of care these practices require. This innovating treatment emphasises the need of continued care, responsability, sense of autonomy and increases nursing skills and abilities. It requires very specific approaches dealing with these post-transplants complications. From the preliminary results of our Unit can conclude that our practice is effective and necessary.
STI: Signal Transduction Inhibitor

E. Dannie (London, UK)
The great majority of cases of chronic myeloid leukaemia (CML) are characterised by the presence of the Philadelphia chromosome. The translocation t (9:22) leads to the production of the bcr-ab1 tyrosine kinase, which is thought to be responsible for the malignant transformation. The signal transduction inhibitor, ST1 57I, specifically inhibits the bcr-ab1 tyrosine kinase and may provide a remarkably effective way of controlling this disease.
Throughout the world patients have been enrolled in a number of protocols for chronic accelerated and blastic phases. In general the drug has been tolerated well. Reported adverse effects include nausea, arthralgia, myalgia, rashes, periorbital oedema and pancytopenia. Most side effects resolve by reducing or temporarily discontinuing treatment.
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Clinical trials began at our hospital earlier this year. Information concerning this new agent was readily available in the media and on the Internet, and patients had high expectations of its efficacy. A powerful patient lobby began which has contributed to the increased availability of the drug in expanded access studies. As a result we have recruited patients to these studies more rapidly and in larger numbers than for any previous clinical trials in our department.
This has resulted in increased pressures on our staff, and a number of issues required urgent resolution. Extra medical and nursing staff were recruited and a new clinic was established. This in turn required additional clerical and secretarial support. The structure of the studies demand frequent follow up visits but a medical opinion is not required at all times. We have therefore developed a nurse led clinic.
There were also additional pressures on the laboratory staff, to report blood films, perform and report bone marrow aspirates and trephines and carry out regular cytogenetic analyses. Patients in advanced phases of the disease often require supportive care with antibiotics and blood products. This in turn led to a reorganisation of daycare activities.
In summery the incorporation of this clinic into a busy haematology practice provided many challenges. However with planning, co ordination, co-operation and adequate financial reimbursement, the studies are now running satisfactorily. These trials have not only created new hope for patients but improved our availability to cope with new demands and challenges.
